In the last trading session, 1.24 million Galera Therapeutics Inc (NASDAQ:GRTX) shares changed hands as the company’s beta touched 2.17. With the company’s per share price at $0.14 changed hands at $0.0 or -3.46% during last session, the market valuation stood at $7.59M. GRTX’s last price was a discount, traded about -2464.29% off its 52-week high of $3.59. The share price had its 52-week low at $0.09, which suggests the last value was 35.71% up since then. When we look at Galera Therapeutics Inc’s average trading volume, we note the 10-day average is 3.66 million shares, with the 3-month average coming to 4.74 million.

Analysts gave the Galera Therapeutics Inc (GRTX) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended GRTX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Galera Therapeutics Inc’s EPS for the current quarter is expected to be -$0.27.

Galera Therapeutics Inc (NASDAQ:GRTX) trade information

Instantly GRTX was in red as seen at the end of in last trading. With action 12.50%, the performance over the past five days has been green. The drop to weekly highs of 0.1509 on Friday, 11/17/23 subtracted -3.46% to the stock’s daily price. The company’s shares are showing year-to-date downside of -90.64%, with the 5-day performance at 12.50% in the green. However, in the 30-day time frame, Galera Therapeutics Inc (NASDAQ:GRTX) is -41.80% down. Looking at the short shares, we see there were 2.87 million shares sold at short interest cover period of 0.43 days.

The consensus price target for the stock as assigned by Wall Street analysts is $0.35, meaning bulls need an upside of 60.0% from its current market value. According to analyst projections, GRTX’s forecast low is $0.25 with $0.50 as the target high. To hit the forecast high, the stock’s price needs a -257.14% plunge from its current level, while the stock would need to soar -78.57% for it to hit the projected low.

Galera Therapeutics Inc (GRTX) estimates and forecasts

Data shows that the Galera Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -95.41% over the past 6 months, a 27.83% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Galera Therapeutics Inc will rise 53.40%, while the growth in revenue is estimated to hit 54.00% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.44%. The 2023 estimates are for Galera Therapeutics Inc earnings to increase by 26.20%, but the outlook for the next 5-year period is at 34.40% per year.

GRTX Dividends

Galera Therapeutics Inc is expected to release its next quarterly earnings report on November 14.

Galera Therapeutics Inc (NASDAQ:GRTX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 9.56% of Galera Therapeutics Inc shares while 46.38% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 51.28%. There are 46.38% institutions holding the Galera Therapeutics Inc stock share, with Sofinnova Investments, Inc. the top institutional holder. As of Jun 29, 2023, the company held 7.02% of the shares, roughly 3.08 million GRTX shares worth $9.62 million.

Novo Holdings A/S holds the second largest percentage of outstanding shares, with 4.78% or 2.1 million shares worth $6.55 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Tekla Healthcare Opportunities Fund. With 1.05 million shares estimated at $3.28 million under it, the former controlled 2.40% of total outstanding shares. On the other hand, Tekla Healthcare Opportunities Fund held about 0.72% of the shares, roughly 0.31 million shares worth around $0.98 million.